Prophylactic cefazolin in amnioinfusions administered for meconium-stained amniotic fluid.
OBJECTIVE
To determine if amnioinfusion with an antibiotic solution decreased the rate of clinical chorioamnionitis and puerperal endometritis in patients with meconium-stained amniotic fluid.


METHODS
Patients in labor at 36 weeks of gestation or greater with singleton pregnancies and meconium-stained amniotic fluid were randomized to receive either cefazolin, 1 g/1,000 mL, of normal saline (n = 90) or normal saline (n = 93) amnioinfusion. Rates of clinically diagnosed chorioamnionitis and endometritis and of suspected and culture-proven neonatal infection were determined.


RESULTS
Between the study and control groups, the incidences of clinical chorioamnionitis (7.8% vs. 8.6%), endometritis (2.4% vs. 3.5%), aggregate intrauterine infection (10.0% vs. 11.8%), suspected neonatal infection (17.8% vs. 21.5%), and proven neonatal infection (0.0% vs. 2.2%) were not significantly different.


CONCLUSIONS
Prophylactic use of cefazolin in amnioinfusions did not significantly reduce rates of maternal or neonatal infection in patients with meconium-stained amniotic fluid.
Edwards
R K
RK
Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville 32610-0294, USA.
Duff
P
P
D000328:Adult; D000653:Amniotic Fluid; D002437:Cefazolin / Q000008:administration & dosage*; D002511:Cephalosporins / Q000008:administration & dosage*; D002821:Chorioamnionitis / Q000517:prevention & control*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004716:Endometritis / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008470:Meconium; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control*; D011446:Prospective Studies
D002511:Cephalosporins; D002437:Cefazolin